Details of the Drug

General Information of Drug (ID: DML4ZOT)

• Drug Name: Lidocaine
• Synonyms: Alphacaine; Anestacon; Cappicaine; Cuivasil; Dalcaine; Dentipatch; DermaFlex; Dilocaine; Duncaine; EMBOLEX; Esracaine; Gravocain; Isicaina; Isicaine; Jetocaine; LIDOPEN; LQZ; Lanabiotic; Leostesin; Lidocaina; Lidocainum; Lidocaton; Lidoderm; Lignocaine; Lignocainum; Lingocaine; Maricaine; Octocaine; Remicaine; Rucaina; Solcain; Xilina; Xilocaina; Xllina; Xycaine; Xylestesin; Xylesthesin; Xylocain; Xylocaine; Xylocard; Xylocitin; Xylotox; Zingo; After Burn Double Strength Gel; After Burn Double Strength Spray; After Burn Gel; After Burn Spray; Anestacon Jelly; Cito optadren; Emla Cream; Lidocaine Carbonate; Lidocaine Hydrocarbonate; Lidocaine Monohydrochloride; Norwood Sunburn Spray; Rocephin Kit; Solarcaine aloe extraburn relief cream; Xilocaina [Italian]; Xylocaine Dental Ointment; Xylocaine Endotracheal; Xylocaine Test Dose; Xylocaine Viscous; CDS1_000283; L1026_SIGMA; Xylocaine CO2; Dentipatch (TN); ELA-Max; L-Caine; Lida-Mantle; Lidocaina [INN-Spanish]; Lidocaine (VAN); Lidocainum [INN-Latin]; Lidoject-1; Lidoject-2; Octocaine-100; Octocaine-50; Xylocaine (TN); Xylocaine 5% Spinal; Xylocaine-Mpf; Xylocaine-Mpf with Glucose; Xyloneural (free base); Zilactin-L; Lidocaine [USAN:INN:JAN]; Diethylaminoaceto-2,6-xylidide; Lidocaine (JP15/USP/INN); Alfa-Dietilamino-2,6-dimetilacetanilide; Alfa-Dietilamino-2,6-dimetilacetanilide [Italian]; Alpha-Diethylamino-2,6-dimethylacetanilide; Alpha-Diethylaminoaceto-2,6-xylidide; LIDOCAINE (73-58-6 (MONOHYDROCHLORIDE); Omega-Diethylamino-2,6-dimethylacetanilide; Alpha-(Diethylamino)-2,6-acetoxylidide; N-(2,6-dimethylphenyl)-N(2),N(2)-diethylglycinamide; N-(2,6-dimethylphenyl)-N~2~,N~2~-diethylglycinamide; 2-(Diethylamino)-2',6'-acetoxylidide; 2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide; 2-Diethylamino-N-(2,6-dimethyl-phenyl)-acetamide; 2-Diethylamino-N-(2,6-dimethylphenyl)acetamide

Indication

Disease Entry	ICD 11	Status	REF
Anaesthesia	9A78.6	Approved	[1], [2]
Dysmenorrhea	GA34.3	Phase 2	[3]

• Therapeutic Class: Anesthetics
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 234.34
  Topological Polar Surface Area (xlogp); 2.3
  Rotatable Bond Count (rotbonds); 5
  Hydrogen Bond Donor Count (hbonddonor); 1
  Hydrogen Bond Acceptor Count (hbondacc); 2
• ADMET Property:
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
  Clearance: The sytemic clearance of drug is 0.64 +/- 0.18 L/min [5]
  Elimination: The excretion of unchanged lidocaine and its metabolites occurs predominantly via the kidney with less than 5% in the unchanged form appearing in the urine [6]
  Half-life: The concentration or amount of drug in body reduced by one-half in 1.5 - 2 hours [7]
  Metabolism: The drug is metabolized via the liver [7]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 18.2884 micromolar/kg/day [8]
  Unbound Fraction: The unbound fraction of drug in plasma is 0.33% [9]
  Vd: The volume of distribution (Vd) of drug is 0.7-1.5 L/kg [10]
  Water Solubility: The ability of drug to dissolve in water is measured as 3.58 mg/mL [4]
• Chemical Identifiers:
  Formula: C14H22N2O
  IUPAC Name: 2-(diethylamino)-N-(2,6-dimethylphenyl)acetamide
  Canonical SMILES: CCN(CC)CC(=O)NC1=C(C=CC=C1C)C
  InChI: InChI=1S/C14H22N2O/c1-5-16(6-2)10-13(17)15-14-11(3)8-7-9-12(14)4/h7-9H,5-6,10H2,1-4H3,(H,15,17)
  InChIKey: NNJVILVZKWQKPM-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 3676
  ChEBI ID: CHEBI:6456
  CAS Number: 137-58-6
  DrugBank ID: DB00281
  TTD ID: D0X4RN
  VARIDT ID: DR00849
  INTEDE ID: DR0953

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Voltage-gated sodium channel alpha Nav1.9 (SCN11A)	TTN9VTF	SCNBA_HUMAN	Blocker	[11], [12]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[13]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[14]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[15]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[16]
Cytochrome P450 2A6 (CYP2A6)	DEJVYAZ	CP2A6_HUMAN	Substrate	[16]
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Substrate	[17]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[18]
Cytochrome P450 2B6 (CYP2B6)	DEPKLMQ	CP2B6_HUMAN	Substrate	[19]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Substrate	[16]
Cytochrome P450 3A7 (CYP3A7)	DERD86B	CP3A7_HUMAN	Substrate	[18]
Cytochrome P450 2C18 (CYP2C18)	DEZMWRE	CP2CI_HUMAN	Substrate	[16]

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Lidocaine

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Atracurium	DM42HXN	Moderate	Additive neuromuscular blocking effects by the combination of Lidocaine and Atracurium.	Corneal disease [9A76-9A78]	[102]
Mivacurium	DM473VD	Moderate	Additive neuromuscular blocking effects by the combination of Lidocaine and Mivacurium.	Corneal disease [9A76-9A78]	[102]
Pancuronium	DMB0VY8	Moderate	Additive neuromuscular blocking effects by the combination of Lidocaine and Pancuronium.	Corneal disease [9A76-9A78]	[102]
Tubocurarine	DMBZIVP	Moderate	Additive neuromuscular blocking effects by the combination of Lidocaine and Tubocurarine.	Corneal disease [9A76-9A78]	[102]
Alfentanil	DMVO0UB	Minor	Decreased metabolism of Lidocaine caused by Alfentanil mediated inhibition of CYP450 enzyme.	Corneal disease [9A76-9A78]	[103]

Coadministration of a Drug Treating the Disease Different from Lidocaine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Minor	Increased metabolism of Lidocaine caused by Ivosidenib mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[104]
Arn-509	DMT81LZ	Minor	Increased metabolism of Lidocaine caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[104]
Emapalumab	DMZG5WL	Moderate	Altered metabolism of Lidocaine due to Emapalumab alters the formation of CYP450 enzymes.	Adaptive immunity immunodeficiency [4A01]	[105]
Mitotane	DMU1GX0	Minor	Increased metabolism of Lidocaine caused by Mitotane mediated induction of CYP450 enzyme.	Adrenal cancer [2D11]	[104]
Siltuximab	DMGEATB	Moderate	Altered metabolism of Lidocaine due to Siltuximab alters the formation of CYP450 enzymes.	Anemia [3A00-3A9Z]	[105]
Dronedarone	DMA8FS5	Moderate	Decreased metabolism of Lidocaine caused by Dronedarone mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[106]
Methylphenobarbital	DMDSWAG	Minor	Increased metabolism of Lidocaine caused by Methylphenobarbital mediated induction of CYP450 enzyme.	Anxiety disorder [6B00-6B0Z]	[104]
Voriconazole	DMAOL2S	Moderate	Decreased metabolism of Lidocaine caused by Voriconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[107]
Posaconazole	DMUL5EW	Moderate	Decreased metabolism of Lidocaine caused by Posaconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[105]
Obeticholic acid	DM3Q1SM	Moderate	Decreased metabolism of Lidocaine caused by Obeticholic acid mediated inhibition of CYP450 enzyme.	Autoimmune liver disease [DB96]	[108]
Telithromycin	DMZ4P3A	Moderate	Decreased metabolism of Lidocaine caused by Telithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[109]
Pexidartinib	DMS2J0Z	Minor	Increased metabolism of Lidocaine caused by Pexidartinib mediated induction of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[104]
Nitazoxanide	DMOWLVG	Moderate	Increased plasma concentration of Lidocaine and Nitazoxanide due to competitive binding of plasma proteins.	Bowel habit change [ME05]	[110]
Lapatinib	DM3BH1Y	Moderate	Decreased clearance of Lidocaine due to the transporter inhibition by Lapatinib.	Breast cancer [2C60-2C6Y]	[111]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Lidocaine caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[112]
Secobarbital	DM14RF5	Minor	Increased metabolism of Lidocaine caused by Secobarbital mediated induction of CYP450 enzyme.	Chronic insomnia [7A00]	[104]
Phenylbutazone	DMAYL0T	Minor	Increased metabolism of Lidocaine caused by Phenylbutazone mediated induction of CYP450 enzyme.	Chronic pain [MG30]	[104]
Mifepristone	DMGZQEF	Moderate	Decreased metabolism of Lidocaine caused by Mifepristone mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[107]
Pasireotide	DMHM7JS	Moderate	Increased risk of bradycardia by the combination of Lidocaine and Pasireotide.	Cushing syndrome [5A70]	[113]
Osilodrostat	DMIJC9X	Moderate	Decreased metabolism of Lidocaine caused by Osilodrostat mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[114]
Aminoglutethimide	DMWFHMZ	Minor	Increased metabolism of Lidocaine caused by Aminoglutethimide mediated induction of CYP450 enzyme.	Cushing syndrome [5A70]	[104]
Ivacaftor	DMZC1HS	Moderate	Decreased clearance of Lidocaine due to the transporter inhibition by Ivacaftor.	Cystic fibrosis [CA25]	[115]
Aprepitant	DM053KT	Moderate	Decreased metabolism of Lidocaine caused by Aprepitant mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[116]
Nefazodone	DM4ZS8M	Moderate	Decreased metabolism of Lidocaine caused by Nefazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[117]
Griseofulvin	DMK54YG	Minor	Increased metabolism of Lidocaine caused by Griseofulvin mediated induction of CYP450 enzyme.	Dermatophytosis [1F28]	[104]
Primidone	DM0WX6I	Minor	Increased metabolism of Lidocaine caused by Primidone mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[104]
Felbamate	DM1V5ZS	Minor	Increased metabolism of Lidocaine caused by Felbamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[104]
Oxcarbazepine	DM5PU6O	Minor	Increased metabolism of Lidocaine caused by Oxcarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[104]
Cenobamate	DMGOVHA	Minor	Increased metabolism of Lidocaine caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[104]
Rufinamide	DMWE60C	Minor	Increased metabolism of Lidocaine caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[104]
Phenobarbital	DMXZOCG	Minor	Increased metabolism of Lidocaine caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[105]
Carbamazepine	DMZOLBI	Minor	Increased metabolism of Lidocaine caused by Carbamazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[104]
Tazemetostat	DMWP1BH	Minor	Increased metabolism of Lidocaine caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[104]
Itraconazole	DMCR1MV	Moderate	Decreased metabolism of Lidocaine caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[118]
Omeprazole	DM471KJ	Minor	Increased metabolism of Lidocaine caused by Omeprazole mediated induction of CYP450 enzyme.	Gastro-oesophageal reflux disease [DA22]	[104]
Cimetidine	DMH61ZB	Moderate	Decreased metabolism of Lidocaine caused by Cimetidine mediated inhibition of CYP450 enzyme.	Gastro-oesophageal reflux disease [DA22]	[119]
Sulfinpyrazone	DMEV954	Minor	Increased metabolism of Lidocaine caused by Sulfinpyrazone mediated induction of CYP450 enzyme.	Gout [FA25]	[104]
Rifampin	DMA8J1G	Minor	Increased metabolism of Lidocaine caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[104]
Rifapentine	DMCHV4I	Minor	Increased metabolism of Lidocaine caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[104]
Delavirdine	DM3NF5G	Moderate	Decreased metabolism of Lidocaine caused by Delavirdine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[120]
Fosamprenavir	DM4W9B3	Major	Decreased metabolism of Lidocaine caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[113]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Lidocaine caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[105]
Efavirenz	DMC0GSJ	Minor	Increased metabolism of Lidocaine caused by Efavirenz mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[104]
Saquinavir	DMG814N	Major	Decreased metabolism of Lidocaine caused by Saquinavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[121]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Lidocaine caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[122]
Amprenavir	DMLMXE0	Major	Decreased metabolism of Lidocaine caused by Amprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[113]
Darunavir	DMN3GCH	Moderate	Decreased metabolism of Lidocaine caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[123]
Atazanavir	DMSYRBX	Moderate	Decreased metabolism of Lidocaine caused by Atazanavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[107]
Ritonavir	DMU764S	Moderate	Decreased metabolism of Lidocaine caused by Ritonavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[124]
Teriflunomide	DMQ2FKJ	Minor	Increased metabolism of Lidocaine caused by Teriflunomide mediated induction of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[104]
Conivaptan	DM1V329	Major	Decreased metabolism of Lidocaine caused by Conivaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[125]
Givosiran	DM5PFIJ	Moderate	Decreased metabolism of Lidocaine caused by Givosiran mediated inhibition of CYP450 enzyme.	Inborn porphyrin/heme metabolism error [5C58]	[126]
Amobarbital	DM0GQ8N	Minor	Increased metabolism of Lidocaine caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[104]
Pentobarbital	DMFNH7L	Minor	Increased metabolism of Lidocaine caused by Pentobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[104]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of lowers seizure threshold by the combination of Lidocaine and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[127]
Raloxifene	DMDKF3M	Minor	Increased plasma concentration of Lidocaine and Raloxifene due to competitive binding of plasma proteins.	Low bone mass disorder [FB83]	[128]
Ceritinib	DMB920Z	Moderate	Decreased metabolism of Lidocaine caused by Ceritinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[105]
PF-06463922	DMKM7EW	Minor	Increased metabolism of Lidocaine caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[104]
Osimertinib	DMRJLAT	Minor	Increased metabolism of Lidocaine caused by Osimertinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[104]
Capmatinib	DMYCXKL	Moderate	Decreased metabolism of Lidocaine caused by Capmatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[129]
Selpercatinib	DMZR15V	Moderate	Decreased metabolism of Lidocaine caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[130]
Idelalisib	DM602WT	Moderate	Decreased metabolism of Lidocaine caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[131]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Lidocaine caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[132]
Vemurafenib	DM62UG5	Minor	Increased metabolism of Lidocaine caused by Vemurafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[104]
Dabrafenib	DMX6OE3	Minor	Increased metabolism of Lidocaine caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[104]
Exjade	DMHPRWG	Minor	Increased metabolism of Lidocaine caused by Exjade mediated induction of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[104]
Rifabutin	DM1YBHK	Minor	Increased metabolism of Lidocaine caused by Rifabutin mediated induction of CYP450 enzyme.	Mycobacterium infection [1B10-1B21]	[104]
Bexarotene	DMOBIKY	Minor	Increased metabolism of Lidocaine caused by Bexarotene mediated induction of CYP450 enzyme.	Mycosis fungoides [2B01]	[104]
Imatinib	DM7RJXL	Moderate	Decreased metabolism of Lidocaine caused by Imatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[133]
Dasatinib	DMJV2EK	Moderate	Decreased metabolism of Lidocaine caused by Dasatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[134]
Modafinil	DMYILBE	Minor	Increased metabolism of Lidocaine caused by Modafinil mediated induction of CYP450 enzyme.	Narcolepsy [7A20]	[104]
Bupropion	DM5PCS7	Major	Increased risk of lowers seizure threshold by the combination of Lidocaine and Bupropion.	Nicotine use disorder [6C4A]	[135]
Olaparib	DM8QB1D	Moderate	Increased metabolism of Lidocaine caused by Olaparib mediated induction of CYP450 enzyme.	Ovarian cancer [2C73]	[107]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Lidocaine caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[136]
Prilocaine	DMI7DZ2	Major	Increased risk of methemoglobinemia by the combination of Lidocaine and Prilocaine.	Pain [MG30-MG3Z]	[137]
Albendazole	DMYZ57N	Minor	Increased metabolism of Lidocaine caused by Albendazole mediated induction of CYP450 enzyme.	Parasitic worm infestation [1F90]	[104]
Dopamine	DMPGUCF	Minor	Increased metabolism of Lidocaine caused by Dopamine.	Parkinsonism [8A00]	[138]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Lidocaine caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[139]
Lindane	DMB8CNL	Moderate	Increased risk of lowers seizure threshold by the combination of Lidocaine and Lindane.	Pediculosis [1G00]	[140]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Lidocaine caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[141]
Lonafarnib	DMGM2Z6	Moderate	Decreased metabolism of Lidocaine caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[142]
Enzalutamide	DMGL19D	Minor	Increased metabolism of Lidocaine caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[104]
Ustekinumab	DMHTYK3	Moderate	Altered metabolism of Lidocaine due to Ustekinumab alters the formation of CYP450 enzymes.	Psoriasis [EA90]	[105]
Ixekizumab	DMXW92T	Moderate	Altered metabolism of Lidocaine due to Ixekizumab alters the formation of CYP450 enzymes.	Psoriasis [EA90]	[105]
Bosentan	DMIOGBU	Minor	Increased metabolism of Lidocaine caused by Bosentan mediated induction of CYP450 enzyme.	Pulmonary hypertension [BB01]	[104]
Temsirolimus	DMS104F	Moderate	Increased plasma concentrations of Lidocaine and Temsirolimus due to competitive inhibition of the same metabolic pathway.	Renal cell carcinoma [2C90]	[143]
Tocilizumab	DM7J6OR	Moderate	Altered metabolism of Lidocaine due to Tocilizumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[105]
Canakinumab	DM8HLO5	Moderate	Altered metabolism of Lidocaine due to Canakinumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[105]
Rilonacept	DMGLUQS	Moderate	Altered metabolism of Lidocaine due to Rilonacept alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[105]
Golimumab	DMHZV7X	Moderate	Altered metabolism of Lidocaine due to Golimumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[105]
Dexamethasone	DMMWZET	Minor	Increased metabolism of Lidocaine caused by Dexamethasone mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[104]
Nafcillin	DMN9RPO	Minor	Increased metabolism of Lidocaine caused by Nafcillin mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[104]
Sarilumab	DMOGNXY	Moderate	Altered metabolism of Lidocaine due to Sarilumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[105]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Lidocaine caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[107]
Armodafinil	DMGB035	Minor	Increased metabolism of Lidocaine caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[104]
Ibutilide	DMKXY2R	Moderate	Increased risk of bradycardia by the combination of Lidocaine and Ibutilide.	Supraventricular tachyarrhythmia [BC81]	[144]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Lidocaine caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[145]
Lusutrombopag	DMH6IKO	Moderate	Decreased clearance of Lidocaine due to the transporter inhibition by Lusutrombopag.	Thrombocytopenia [3B64]	[136]
Pipecuronium	DM5F84A	Moderate	Additive neuromuscular blocking effects by the combination of Lidocaine and Pipecuronium.	Tonus and reflex abnormality [MB47]	[102]
Doxacurium	DMKE7L9	Moderate	Additive neuromuscular blocking effects by the combination of Lidocaine and Doxacurium.	Tonus and reflex abnormality [MB47]	[102]
Vecuronium	DMP0UK2	Moderate	Additive neuromuscular blocking effects by the combination of Lidocaine and Vecuronium.	Tonus and reflex abnormality [MB47]	[102]
Cisatracurium	DMUZPJ5	Moderate	Additive neuromuscular blocking effects by the combination of Lidocaine and Cisatracurium.	Tonus and reflex abnormality [MB47]	[102]
Rocuronium	DMY9BMK	Moderate	Additive neuromuscular blocking effects by the combination of Lidocaine and Rocuronium.	Tonus and reflex abnormality [MB47]	[102]
Sirolimus	DMGW1ID	Moderate	Increased plasma concentrations of Lidocaine and Sirolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[143]
Tacrolimus	DMZ7XNQ	Moderate	Increased plasma concentrations of Lidocaine and Tacrolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[143]
Elagolix	DMB2C0E	Minor	Increased metabolism of Lidocaine caused by Elagolix mediated induction of CYP450 enzyme.	Uterine fibroid [2E86]	[104]
Bretylium	DM1FX74	Moderate	Increased risk of atrioventricular block by the combination of Lidocaine and Bretylium.	Ventricular tachyarrhythmia [BC71]	[144]
Amiodarone	DMUTEX3	Moderate	Decreased metabolism of Lidocaine caused by Amiodarone mediated inhibition of CYP450 enzyme.	Ventricular tachyarrhythmia [BC71]	[146]
Tocainide	DMYNMDP	Moderate	Additive CNS depression effects by the combination of Lidocaine and Tocainide.	Ventricular tachyarrhythmia [BC71]	[147]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2623).
• [2] An absorbable local anesthetic matrix provides several days of functional sciatic nerve blockade. Anesth Analg. 2009 Mar;108(3):1027-33.
• [3] ClinicalTrials.gov (NCT00651313) Efficacy and Safety Study of Lidocaine Vaginal Gel for Recurrent Dysmenorrhea (Painful Periods). U.S. National Institutes of Health.
• [4] BDDCS applied to over 900 drugs
• [5] An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
• [6] Electronic Medicines Compendium: Lidocaine 1% w/v solution for injection Monograph
• [7] FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
• [8] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [9] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [10] StatPearls Internet: Lidocaine Profile
• [11] Mechanisms of analgesia of intravenous lidocaine. Rev Bras Anestesiol. 2008 May-Jun;58(3):280-6.
• [12] Lidocaine inhibits epithelial chemokine secretion via inhibition of nuclear factor kappa B activation. Immunobiology. 2010 Apr;215(4):304-13.
• [13] Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
• [14] Pharmacokinetics of lidocaine hydrochloride metabolized by CYP3A4 in Chinese Han volunteers living at low altitude and in native Han and Tibetan Chinese volunteers living at high altitude. Pharmacology. 2016;97(3-4):107-13.
• [15] Involvement of CYP1A2 and CYP3A4 in lidocaine N-deethylation and 3-hydroxylation in humans. Drug Metab Dispos. 2000 Aug;28(8):959-65.
• [16] Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
• [17] Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218.
• [18] Drug Interactions Flockhart Table
• [19] Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):413-425.
• [20] Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
• [21] Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
• [22] Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
• [23] Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
• [24] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [25] Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
• [26] Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
• [27] The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
• [28] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [29] Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
• [30] Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
• [31] Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
• [32] Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
• [33] PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
• [34] The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
• [35] The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
• [36] Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
• [37] Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
• [38] Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis. 1994 Jan;15(1):5-9.
• [39] Psychotropic drug interactions with valproate. Clin Neuropharmacol. 2005 Mar-Apr;28(2):96-101.
• [40] The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
• [41] Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
• [42] CYP2A6- and CYP2A13-catalyzed metabolism of the nicotine delta-5'(1')iminium ion. J Pharmacol Exp Ther. 2012 Nov;343(2):307-15.
• [43] Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
• [44] Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
• [45] CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
• [46] Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
• [47] Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
• [48] Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
• [49] Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
• [50] Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
• [51] Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
• [52] Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
• [53] Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
• [54] Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
• [55] Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
• [56] Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
• [57] Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
• [58] Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
• [59] The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
• [60] Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
• [61] Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
• [62] Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites. Mol Pharmacol. 2000 Dec;58(6):1341-8.
• [63] Targeted antipeptide antibodies to cytochrome P450 2C18 based on epitope mapping of an inhibitory monoclonal antibody to P450 2C51. Arch Biochem Biophys. 1997 Feb 15;338(2):157-64.
• [64] Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol. 1996 Mar;9(2):365-73.
• [65] CYP2C8/9 mediate dapsone N-hydroxylation at clinical concentrations of dapsone. Drug Metab Dispos. 2000 Aug;28(8):865-8.
• [66] Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab Dispos. 2001 Mar;29(3):242-51.
• [67] Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos. 1999 Jun;27(6):655-66.
• [68] Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
• [69] Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
• [70] Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
• [71] Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
• [72] PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
• [73] Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
• [74] Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
• [75] Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
• [76] Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
• [77] Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
• [78] New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
• [79] A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
• [80] A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
• [81] Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J Pharmacol Exp Ther. 2002 Jun;301(3):945-52.
• [82] Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol. 1999 Sep 1;58(5):787-96.
• [83] Drugs that may have potential CYP2B6 interactions.
• [84] Involvement of human cytochrome P450 2B6 in the omega- and 4-hydroxylation of the anesthetic agent propofol. Xenobiotica. 2007 Jul;37(7):717-24.
• [85] Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-butanone metabolism by cytochrome P450 2B6. Drug Metab Dispos. 2005 Dec;33(12):1760-4.
• [86] PharmGKB summary: phenytoin pathway. Pharmacogenet Genomics. 2012 Jun;22(6):466-70.
• [87] Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther. 2001 Apr;297(1):326-37.
• [88] Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
• [89] MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
• [90] Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
• [91] Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
• [92] Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
• [93] Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
• [94] The effects of lamotrigine on the acquisition and expression of morphine-induced place preference in mice. Pak J Biol Sci. 2009 Jan 1;12(1):33-9.
• [95] Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
• [96] Secondary injury mechanisms of spinal cord trauma: a novel therapeutic approach for the management of secondary pathophysiology with the sodium channel blocker riluzole. Prog Brain Res. 2002;137:177-90.
• [97] Tolperisone-type drugs inhibit spinal reflexes via blockade of voltage-gated sodium and calcium channels. J Pharmacol Exp Ther. 2005 Dec;315(3):1237-46.
• [98] New antiarrhythmic agents for atrial fibrillation and atrial flutter. Expert Opin Emerg Drugs. 2005 May;10(2):311-22.
• [99] Debate: Does genetic information in humans help us treat patients PRO--genetic information in humans helps us treat patients. CON--genetic information does not help at all. Epilepsia. 2008 Dec;49 Suppl 9:13-24.
• [100] Emerging drugs for spinal cord injury. Expert Opin Emerg Drugs. 2008 Mar;13(1):63-80.
• [101] Voltage-gated sodium channel blockers for the treatment of chronic pain. Curr Top Med Chem. 2009;9(4):362-76.
• [102] Bruckner J, Thomas KC, Bikhazi GB, Foldes FF "Neuromuscular drug interactions of clinical importance." Anesth Analg 59 (1980): 678-82. [PMID: 7191227]
• [103] Kharasch ED, Thummel KE "Human alfentanil metabolism by cytochrome P450 3A3/4. An explanation for the interindividual variability in alfentanil clearance?" Anesth Analg 76 (1993): 1033-9. [PMID: 8484504]
• [104] Heinonen J, Takki S, Jarho L "Plasma lidocaine levels in patients treated with potential inducers of microsomal enzymes." Acta Anaesthesiol Scand 14 (1970): 89-95. [PMID: 5428253]
• [105] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [106] Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
• [107] Cerner Multum, Inc. "Australian Product Information.".
• [108] Product Information. Ocaliva (obeticholic acid). Intercept Pharmaceuticals, Inc., New York, NY.
• [109] Product Information. Ketek (telithromycin). Aventis Pharmaceuticals, Bridgewater, NJ.
• [110] Product Information. Alinia (nitazoxanide). Romark Laboratories L.C., Tampa, FL.
• [111] Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
• [112] Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
• [113] Canadian Pharmacists Association.
• [114] Product Information. Isturisa (osilodrostat). Recordati Rare Diseases Inc, Lebanon, NJ.
• [115] Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
• [116] Product Information. Emend (aprepitant). Merck & Company Inc, West Point, PA.
• [117] Product Information. Serzone (nefazodone). Bristol-Myers Squibb, Princeton, NJ.
• [118] Auclair B, Berning SE, Huitt GA, Peloquin CP "Potential interaction between itraconazole and clarithromycin." Pharmacotherapy 19 (1999): 1439-44. [PMID: 10600094]
• [119] Berk SI, Gal P, Bauman JL, et al "The effect of oral cimetidine on total and unbound serum lidocaine concentrations in patients with suspected myocardial infarction." Int J Cardiol 14 (1987): 91-4. [PMID: 3804509]
• [120] Product Information. Rescriptor (delavirdine). Pharmacia and Upjohn, Kalamazoo, MI.
• [121] Product Information. Fortovase (saquinavir) Roche Laboratories, Nutley, NJ.
• [122] Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
• [123] Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
• [124] Olkkola KT, Palkama VJ, Neuvonen PJ "Ritonavir's role in reducing fentanyl clearance and prolonging its half-life." Anesthesiology 91 (1999): 681-5. [PMID: 10485779]
• [125] Product Information. Vaprisol (conivaptan). Cumberland Pharmaceuticals Inc, Nashville, TN.
• [126] Product Information. Givlaari (givosiran). Alnylam Pharmaceuticals, Cambridge, MA.
• [127] Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
• [128] Product Information. Evista (raloxifene). Lilly, Eli and Company, Indianapolis, IN.
• [129] Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
• [130] Product Information. Retevmo (selpercatinib). Lilly, Eli and Company, Indianapolis, IN.
• [131] Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
• [132] Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
• [133] Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
• [134] Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
• [135] Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
• [136] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
• [137] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
• [138] Sprung J, Bourke DL, Schoenwald PK, Whalley D, Gottlieb A, Mascha EJ, Kapural L "Small-dose dopamine increases epidural lidocaine requirements during peripheral vascular surgery in elderly patients." Anesth Analg 90 (2000): 388-92. [PMID: 10648327]
• [139] Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
• [140] Matsuoka LY "Convulsions following application of gamma benzene hexachloride." J Am Acad Dermatol 5 (1981): 98-9. [PMID: 6168673]
• [141] Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
• [142] Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
• [143] Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
• [144] Keidar S, Grenadier E, Palant A "Sinoatrial arrest due to lidocaine injection in sick sinus syndrome during amiodarone administration." Am Heart J 104 (1982): 1384-5. [PMID: 7148661]
• [145] Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
• [146] Ha HR, Candinas R, Stieger B, Meyer UA, Follath F "Interaction between amiodarone and lidocaine." J Cardiovasc Pharmacol 28 (1996): 533-9. [PMID: 8891878]
• [147] Product Information. Tonocard (tocainide). Merck & Co, Inc, West Point, PA.